Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has been given a $50.00 price target by equities researchers at Cantor Fitzgerald in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 110.53% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the stock. BidaskClub raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. Zacks Investment Research cut shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. ValuEngine cut shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, September 18th. Raymond James Financial, Inc. reissued a “strong-buy” rating and set a $36.00 target price on shares of Paratek Pharmaceuticals in a report on Thursday, August 24th. Finally, HC Wainwright boosted their target price on shares of Paratek Pharmaceuticals from $36.00 to $43.00 and gave the company a “buy” rating in a report on Tuesday, July 18th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $37.44.

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) traded up 1.89% during midday trading on Tuesday, reaching $24.20. The company had a trading volume of 142,877 shares. The firm’s market capitalization is $671.82 million. The company has a 50 day moving average price of $25.56 and a 200-day moving average price of $22.81. Paratek Pharmaceuticals has a one year low of $9.80 and a one year high of $29.00.

Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.25. The business had revenue of $7.51 million for the quarter, compared to the consensus estimate of $7.50 million.

WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/17/paratek-pharmaceuticals-inc-prtk-given-a-50-00-price-target-at-cantor-fitzgerald.html.

Several institutional investors have recently added to or reduced their stakes in the company. Broadfin Capital LLC increased its holdings in shares of Paratek Pharmaceuticals by 23.7% in the second quarter. Broadfin Capital LLC now owns 277,020 shares of the specialty pharmaceutical company’s stock worth $6,676,000 after purchasing an additional 53,158 shares during the period. California State Teachers Retirement System increased its holdings in shares of Paratek Pharmaceuticals by 7.2% in the second quarter. California State Teachers Retirement System now owns 41,722 shares of the specialty pharmaceutical company’s stock worth $1,006,000 after purchasing an additional 2,800 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Paratek Pharmaceuticals by 21.0% in the second quarter. The Manufacturers Life Insurance Company now owns 18,650 shares of the specialty pharmaceutical company’s stock worth $449,000 after purchasing an additional 3,233 shares during the period. State Street Corp increased its holdings in shares of Paratek Pharmaceuticals by 112.3% in the second quarter. State Street Corp now owns 616,112 shares of the specialty pharmaceutical company’s stock worth $14,850,000 after purchasing an additional 325,856 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Paratek Pharmaceuticals by 40.9% in the second quarter. Goldman Sachs Group Inc. now owns 131,723 shares of the specialty pharmaceutical company’s stock worth $3,175,000 after purchasing an additional 38,222 shares during the period. 82.37% of the stock is currently owned by hedge funds and other institutional investors.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.